Literature DB >> 27126545

O-GlcNAcylation: A regulator of tau pathology and neurodegeneration.

Cheng-Xin Gong1, Fei Liu2, Khalid Iqbal2.   

Abstract

O-GlcNAcylation is the posttranslational modification of intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc). The discovery of O-GlcNAc modification of tau and its impact on tau phosphorylation has attracted recent research interest in O-GlcNAc studies in the Alzheimer's disease (AD) field. Modification of proteins by O-GlcNAc occurs extensively in the brain. The expressions and activities of the enzymes catalyzing O-GlcNAc cycling are several-fold higher in the brain than in the peripheral tissues. The O-GlcNAcylation levels of brain proteins including tau are decreased in AD brain, probably due to decreased brain glucose metabolism. The reduction of brain O-GlcNAcylation appears to mediate the molecular mechanism by which decreased brain glucose metabolism contributes to neurodegeneration. Studies on mouse models of tauopathies suggest a neuroprotective role of pharmacological elevation of brain O-GlcNAc, which could potentially be a promising approach for treating AD and other neurodegenerative diseases.
Copyright © 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Hyperphosphorylation; Neurodegeneration; O-GlcNAcylation; Tau

Mesh:

Substances:

Year:  2016        PMID: 27126545     DOI: 10.1016/j.jalz.2016.02.011

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  27 in total

Review 1.  Nutrient regulation of signaling and transcription.

Authors:  Gerald W Hart
Journal:  J Biol Chem       Date:  2019-01-09       Impact factor: 5.157

Review 2.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

Review 3.  The emerging link between O-GlcNAcylation and neurological disorders.

Authors:  Xiaofeng Ma; He Li; Yating He; Junwei Hao
Journal:  Cell Mol Life Sci       Date:  2017-05-22       Impact factor: 9.261

Review 4.  Nutrient-driven O-GlcNAc in proteostasis and neurodegeneration.

Authors:  Ilhan Akan; Stephanie Olivier-Van Stichelen; Michelle R Bond; John A Hanover
Journal:  J Neurochem       Date:  2017-11-20       Impact factor: 5.372

5.  Quantitative proteomics identifies altered O-GlcNAcylation of structural, synaptic and memory-associated proteins in Alzheimer's disease.

Authors:  Sheng Wang; Feng Yang; Vladislav A Petyuk; Anil K Shukla; Matthew E Monroe; Marina A Gritsenko; Karin D Rodland; Richard D Smith; Wei-Jun Qian; Cheng-Xin Gong; Tao Liu
Journal:  J Pathol       Date:  2017-07-28       Impact factor: 7.996

Review 6.  Deciphering the Functions of Protein O-GlcNAcylation with Chemistry.

Authors:  Matthew Worth; Hao Li; Jiaoyang Jiang
Journal:  ACS Chem Biol       Date:  2017-01-19       Impact factor: 5.100

Review 7.  Glycosylation Changes in Brain Cancer.

Authors:  Lucas Veillon; Christina Fakih; Hadi Abou-El-Hassan; Firas Kobeissy; Yehia Mechref
Journal:  ACS Chem Neurosci       Date:  2017-11-07       Impact factor: 4.418

8.  Increased O-GlcNAcylation prevents degeneration of dopamine neurons.

Authors:  Gerald W Hart; Chia-Wei Huang
Journal:  Brain       Date:  2020-12-01       Impact factor: 13.501

9.  Drosophila O-GlcNAcase Mutants Reveal an Expanded Glycoproteome and Novel Growth and Longevity Phenotypes.

Authors:  Ilhan Akan; Adnan Halim; Sergey Y Vakhrushev; Henrik Clausen; John A Hanover
Journal:  Cells       Date:  2021-04-27       Impact factor: 6.600

10.  The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome.

Authors:  Ilaria Zuliani; Chiara Lanzillotta; Antonella Tramutola; Antonio Francioso; Sara Pagnotta; Eugenio Barone; Marzia Perluigi; Fabio Di Domenico
Journal:  Neurotherapeutics       Date:  2020-11-30       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.